The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•9 June 2026•

1 min read

Capital World Investors Builds $430M Stakes in PepsiCo and Moderna

Key Facts

1Capital World Investors purchased 360,436 shares of PepsiCo valued at $51.7 million.

2The firm invested $378.3 million in Moderna by acquiring 12.8 million shares.

3PepsiCo increased its quarterly dividend to $1.48 per share, offering a 4.1% yield.

In a move reflecting institutional confidence in the consumer staples and healthcare sectors, Capital World Investors has disclosed significant new positions in PepsiCo and Moderna. According to reports, the firm acquired 360,436 shares of PepsiCo valued at approximately $51.7 million, coinciding with the company raising its quarterly dividend to $1.48 per share. Additionally, the firm made a larger bet on Moderna, purchasing 12.8 million shares for a total investment of $378.3 million.

These strategic entries come as institutional players seek growth in biotechnology and defensive consumer stocks; PepsiCo continues to compete closely with Coca-Cola, which recently reported an 11% increase in organic revenue per its latest earnings filings. In the vaccine space, Moderna faces ongoing competition from Pfizer, yet this influx of institutional capital provides a potential floor for the stock following a period of intense volatility across the global healthcare sector.

Traders should monitor current price levels, with PEP closing at $142.78 and MRNA at $47.73 (as of June 9, 2026). Looking ahead, market sentiment in consumer-facing sectors may be influenced by upcoming U.S. Initial Jobless Claims data, which serves as a critical gauge for consumer spending resilience and its subsequent impact on value stocks like PepsiCo.